

Ref: FOI/GS/ID 5713

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

12 September 2019

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Biologics and Biosimilar.

You asked:

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs regardless of diagnosis?

Trust response:

Please see populated table below:

| Treatment | Total |
|----------------------------------|-------|
| Abatacept (Orencia) | 83 |
| Adalimumab biosimilar [Amgevita] | 0 |
| Adalimumab biosimilar [Hulio] | 0 |
| Adalimumab [Humira] | 420 |
| Adalimumab biosimilar [Hyrimoz] | 0 |
| Adalimumab biosimilar [Imraldi] | 476 |
| Apremilast (Otezla) | 1 |
| Baricitinib (Olumiant) | 11 |
| Brodalumab (Kyntheum) | 0 |
| Certolizumab (Cimzia) | 33 |
| Dimethyl Fumarate (Skilarence) | 0 |
| Etanercept (Enbrel) | 48 |
| Etanercept Biosimilar (Benepali) | 247 |
| Etanercept Biosimilar (Erelzi) | 0 |
| Golimumab (Simponi) | 133 |
| Guselkumab (Tremfya) | 0 |

| | |
|---------------------------------|-----|
| Infliximab [Flixabi] | 0 |
| Infliximab [Inflectra] | 5 |
| Infliximab [Remicade] | 20 |
| Infliximab [Remsima] | 220 |
| Ixekizumab (Taltz) | 0 |
| Rituximab (Mabthera) | 104 |
| Rituximab Biosimilar (Rixathon) | 0 |
| Rituximab Biosimilar (Truxima) | 259 |
| Sarilumab (Kevzara) | 2 |
| Secukinumab (Cosentyx) | 90 |
| Tildrakizumab (Ilumetri) | 0 |
| Tocilizumab (Ro Actemra) | 86 |
| Tofacitinib (Xeljanz) | 26 |
| Ustekinumab (Stelara) | 37 |
| Vedolizumab (Entyvio) | 67 |